Treatment of Restless Leg Syndrome in Hospitalized Patients

Initial Assessment and Treatment

The American Academy of Sleep Medicine strongly recommends alpha-2-delta ligands (gabapentin, gabapentin enacarbil, or pregabalin) as the first-line pharmacological treatment for hospitalized patients with RLS symptoms, with moderate certainty of evidence and lower risk of long-term complications compared to dopaminergic agents 1
Before initiating any pharmacological treatment, check morning fasting iron studies including serum ferritin and transferrin saturation, and start iron supplementation immediately if ferritin ≤75 ng/mL or transferrin saturation <20% 1
IV ferric carboxymaltose is strongly recommended for rapid correction in hospitalized patients who meet these iron parameters, while oral ferrous sulfate is an alternative option but works more slowly 1

The American Academy of Sleep Medicine recommends gabapentin as a first-line treatment option, with a starting dose of 300 mg three times daily (900 mg/day total) and titration by 300 mg/day every 3-7 days until reaching a maintenance dose of 1800-2400 mg/day divided three times daily 1
Pregabalin is an alternative option, allowing twice-daily dosing with potentially superior bioavailability compared to gabapentin, and is strongly recommended as first-line therapy with moderate certainty of evidence 3

The American Academy of Sleep Medicine recommends against the use of dopamine agonists (pramipexole, ropinirole, rotigotine) due to the significant risk of augmentation with long-term use, and suggests against the standard use of cabergoline, bupropion, carbamazepine, clonazepam, and valproic acid 1
Dopamine agonists may only be considered for short-term use in patients who place higher value on immediate symptom relief and lower value on long-term adverse effects 1

Extended-release oxycodone and other low-dose opioids are conditionally recommended for moderate to severe refractory cases, with evidence showing relatively low risks of abuse and overdose in appropriately screened patients 2

Single nighttime dosing of gabapentin should be avoided, as it fails to address daytime RLS symptoms and provides suboptimal 24-hour coverage, and three-times-daily dosing is necessary for adequate symptom control 2
Dopamine agonists should not be started as first-line therapy due to the risk of augmentation, and if a patient is already on a dopamine agonist, it should not be abruptly discontinued 1
Iron deficiency should be addressed even if ferritin appears "normal", as RLS patients require higher ferritin targets (≥75 ng/mL) than the general population 2